Insider Buying: Paradigm Biopharmaceuticals (ASX:PAR) Insider Buys 153,265 Shares of Stock

Paradigm Biopharmaceuticals Limited (ASX:PAR) insider Paul Rennie purchased 153,265 shares of the firm’s stock in a transaction on Tuesday, February 3rd. The stock was bought at an average cost of A$0.65 per share, with a total value of A$99,622.25.

Paradigm Biopharmaceuticals Price Performance

The firm has a market cap of $196.66 million, a P/E ratio of -2.47 and a beta of 0.94. The company has a debt-to-equity ratio of 1.01, a quick ratio of 5.93 and a current ratio of 7.22.

Paradigm Biopharmaceuticals Company Profile

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.